BioNTech SE (NASDAQ:BNTX) Shares Acquired by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 31.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 97,310 shares of the company’s stock after buying an additional 23,010 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in BioNTech were worth $11,088,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BNTX. Charles Schwab Investment Management Inc. lifted its position in shares of BioNTech by 123.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares in the last quarter. SG Americas Securities LLC raised its stake in BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after purchasing an additional 33,375 shares during the period. Mirabaud & Cie SA purchased a new stake in shares of BioNTech in the fourth quarter valued at $684,000. Redmile Group LLC acquired a new stake in shares of BioNTech in the third quarter worth $18,345,000. Finally, Vestcor Inc purchased a new position in shares of BioNTech during the third quarter valued at $784,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of research reports. BMO Capital Markets upped their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Wells Fargo & Company began coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price for the company. Citigroup began coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target on the stock. Finally, Truist Financial started coverage on BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Stock Performance

BNTX opened at $91.06 on Tuesday. The business’s 50-day simple moving average is $110.99 and its 200 day simple moving average is $113.65. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $21.85 billion, a PE ratio of -43.36 and a beta of 0.30.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the business earned $1.90 EPS. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, sell-side analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.